The stock of Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (SBS) has gone down by -4.68% for the week, with a 10.81% rise in the past month and a 20.78% rise in the past quarter. The volatility ratio for the week is 1.85%, and the volatility levels for the past 30 days are 1.92% for SBS. The simple moving average for the last 20 days is 0.77% for SBS stock, with a simple moving average of 14.25% for the last 200 days.
Is It Worth Investing in Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (NYSE: SBS) Right Now?
Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (NYSE: SBS) has a higher price-to-earnings ratio of 14.60x compared to its average ratio. SBS has 36-month beta value of 1.16. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SBS is 683.42M, and currently, short sellers hold a 0.86% ratio of that float. The average trading volume of SBS on August 29, 2024 was 1.40M shares.
SBS) stock’s latest price update
Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (NYSE: SBS)’s stock price has plunge by -1.14relation to previous closing price of 17.52. Nevertheless, the company has seen a -4.68% plunge in its stock price over the last five trading sessions. accesswire.com reported 2024-08-27 that New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan’s Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar’s novel plant-based prescription drug. “We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS,” said Lisa Conte, Jaguar’s founder, president, and CEO.
SBS Trading at 10.31% from the 50-Day Moving Average
After a stumble in the market that brought SBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.66% of loss for the given period.
Volatility was left at 1.92%, however, over the last 30 days, the volatility rate increased by 1.85%, as shares surge +10.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.96% upper at present.
During the last 5 trading sessions, SBS fell by -4.68%, which changed the moving average for the period of 200-days by +40.58% in comparison to the 20-day moving average, which settled at $17.27. In addition, Companhia de Saneamento Basico do Estado de Sao Paulo. ADR saw 15.66% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SBS
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.4 for the gross margin
The net margin for Companhia de Saneamento Basico do Estado de Sao Paulo. ADR stands at 0.15. The total capital return value is set at 0.13. Equity return is now at value 13.88, with 6.82 for asset returns.
Based on Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (SBS), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is 2.69.
Currently, EBITDA for the company is 9.06 billion with net debt to EBITDA at 1.74. When we switch over and look at the enterprise to sales, we see a ratio of 3.14. The receivables turnover for the company is 6.4for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.36.
Conclusion
To put it simply, Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (SBS) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
